Pharmacokinetics of thrice-weekly rifampicin, isoniazid and pyrazinamide in adult tuberculosis patients in India
Pharmacokinetics of thrice-weekly rifampicin, isoniazid and pyrazinamide in adult tuberculosis patients in India
复制标题
DOI：
10.5588/ijtld.16.0048
复制
发表时间：
2016-09-01
影响因子：
4
通讯作者：
Ramachandran, G.
中科院分区：
文献类型：
--
作者：
Kumar, A. K. Hemanth;Kannan, T.;Ramachandran, G.
目的：为研究利福平（RMP）、异烟肼（INH）和吡嗪酰胺（PZA）在成人结核病患者体内的药代动力学，探讨影响药物药代动力学的因素，对101例接受修订的国家结核病控制规划（RNTCP）每周3次抗结核治疗的成人结核病患者进行研究。本研究在直接观察给药后的稳态下进行。采用高效液相色谱法和实时聚合酶链反应检测NAT2基因分型技术测定RMP、ENE和PZA的浓度。
OBJECTIVE: To study the pharmacokinetics of rifampicin (RMP), isoniazid (INH) and pyrazinamide (PZA) in adult tuberculosis (TB) patients and examine factors that influence drug pharmacokinetics.METHODS: Adult TB patients (n = 101) receiving thrice-weekly anti-tuberculosis treatment in the Revised National TB Control Programme (RNTCP) were studied. The study was conducted at steady state after directly observed drug administration. RMP, ENE and PZA concentrations were estimated using high-performance liquid chromatography and NAT2 genotyping by real-time polymerase chain reaction.RESULTS: RMP peak concentration (C-max) was sub therapeutic (